Yen-Liang Liu

Dr. Yen-Liang Liu

Master Program for Biomedical Engineering, China Medical University, Taichung 40402, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in ACS Nano
Verified
Journal Article
Closed access
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
EPEvan P. Perillo
Evan P. Perillo
PAPhyllis Ang
Phyllis Ang
MKMirae Kim
Mirae Kim
DNDuc Trung Nguyen
Duc Trung Nguyen
HYHsin-Chih Yeh
Hsin-Chih Yeh

1 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
AHAaron M. Horning
Aaron M. Horning
BLBrandon Lieberman
Brandon Lieberman
MKMirae Kim
Mirae Kim
CLChe-Kuang Lin
Che-Kuang Lin
CCChun-Liang Chen
Chun-Liang Chen
Advanced prostate cancer is a very heterogeneous disease reflecting in diverse regulations of oncogenic signaling pathways. Aberrant spatial dynamics of epidermal growth factor receptor (EGFR) promote their dimerization and clustering, leading to constitutive activation in oncogenesis. The EphB2 and Src signaling pathways are associated with the reorganization of the cytoskeleton leading to malignancy, but their roles in regulating EGFR dynamics and activation are scarcely reported. Using single-particle tracking techniques, we found that highly phosphorylated EGFR in the advanced prostate cancer cell line, PC3, was associated with higher EGFR diffusivity, as compared with LNCaP and less aggressive DU145. The increased EGFR activation and biophysical dynamics were consistent with high proliferation, migration, and invasion. After performing single-cell RNA-seq on prostate cancer cell lines and circulating tumor cells from patients, we identified that upregulated gene expression in the EphB2 and Src pathways are associated with advanced malignancy. After dasatinib treatment or siRNA knockdowns of EphB2 or Src, the PC3 cells exhibited significantly lower EGFR dynamics, cell motility, and invasion. Partial inhibitory effects were also found in DU145 cells. The upregulation of parts of the EphB2 and Src pathways also predicts poor prognosis in the prostate cancer patient cohort of The Cancer Genome Atlas. Our results provide evidence that overexpression of the EphB2 and Src signaling pathways regulate EGFR dynamics and cellular aggressiveness in some advanced prostate cancer cells.

25 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
HLHwa-Chang Liu
Hwa-Chang Liu
TLTzu-Shang Liu
Tzu-Shang Liu
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
JWJyh-Horng Wang
Jyh-Horng Wang
CCChih-Hung Chang
Chih-Hung Chang
Feng-Huei LinFeng-Huei Lin
Feng-Huei Lin
We demonstrated the safety and efficacy of autologous chondrocyte precursor (CP) cell therapy in repairing Grade 4 cartilage defects of medial femoral condyles. The autologous bone marrow mesenchymal stem cells of each participant were isolated, amplified, and then differentiated into CPs in atelocollagen. Neotissues made of CPs were implanted into cartilage defects with an average cell density of 4.9 ± 2.1 × 106 cells/cm2 through arthrotomy. The knee function was evaluated with the International Knee Documentation Committee (IKDC) subjective knee form. Patients’ knee functions significantly improved by the 28th week (IKDC score = 68.3 ± 12.1), relative to the initial functionality before the CP therapy (IKDC score = 46.1 ± 16.4, p-value = 0.0014). Nine of these twelve patients maintained good knee functions for 9 years post-implantation (IKDC score = 69.8 ± 12.3) at levels higher than the pre-implantation values (p-value = 0.0018). Patients were evaluated with MRI and arthroscopy, and the defective sites exhibited a smooth surface without a gap between the implant and host tissue. This study demonstrates that autologous CPs successfully engraft into the host tissue and result in the re-formation of hyaline-like cartilage, thereby improving the impaired knee functions. Most importantly, no adverse event was reported during this long-term follow-up period.

15 August 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MKMirae Kim
Mirae Kim
SHSoonwoo Hong
Soonwoo Hong
TYThomas E Yankeelov
Thomas E Yankeelov
HYHsin-Chih Yeh
Hsin-Chih Yeh
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
Motions of transmembrane receptors on cancer cell surfaces can reveal biophysical features of the cancer cells, thus providing a method for characterizing cancer cell phenotypes. While conventional analysis of receptor motions in the cell membrane mostly relies on the mean-squared displacement plots, much information is lost when producing these plots from the trajectories. Here we employ deep learning to classify breast cancer cell types based on the trajectories of epidermal growth factor receptor (EGFR). Our model is an artificial neural network trained on the EGFR motions acquired from six breast cancer cell lines of varying invasiveness and receptor status: MCF7 (hormone receptor positive), BT474 (HER2-positive), SKBR3 (HER2-positive), MDA-MB-468 (triple negative, TN), MDA-MB-231 (TN) and BT549 (TN). The model successfully classified the trajectories within individual cell lines with 83% accuracy and predicted receptor status with 85% accuracy. To further validate the method, epithelial–mesenchymal transition (EMT) was induced in benign MCF10A cells, noninvasive MCF7 cancer cells and highly invasive MDA-MB-231 cancer cells, and EGFR trajectories from these cells were tested. As expected, after EMT induction, both MCF10A and MCF7 cells showed higher rates of classification as TN cells, but not the MDA-MB-231 cells. Whereas deep learning-based cancer cell classifications are primarily based on the optical transmission images of cell morphology and the fluorescence images of cell organelles or cytoskeletal structures, here we demonstrated an alternative way to classify cancer cells using a dynamic, biophysical feature that is readily accessible. A python implementation of deep learning-based classification can be found at https://github.com/soonwoohong/Deep-learning-for-EGFR-trajectory-classification. Supplementary data are available at Bioinformatics online.

19 February 2020 in ACS Sensors
Verified
Journal Article
Closed access
CCChao-Kai Chou
Chao-Kai Chou
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
YCYuan-I Chen
Yuan-I Chen
PHPo-Jung Huang
Po-Jung Huang
PTPei-Hsiang Tsou
Pei-Hsiang Tsou
MHMien-Chie Hung
Mien-Chie Hung

12 December 2025 in Advanced Science
Verified
Journal Article
Open access
YHYu-Nan Huang
Yu-Nan Huang
MTMin‐Yu Tsou
Min‐Yu Tsou
PLPin‐Hung Li
Pin‐Hung Li
JCJo‐Ching Chen
Jo‐Ching Chen
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
PSPen‐Hua Su
Pen‐Hua Su
Evidence on pre‐transplant metabolic therapy remains limited. We evaluated whether concurrent glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) plus sodium–glucose cotransporter 2 inhibitor (SGLT2i) use before solid‐organ transplantation was associated with post‐transplant outcomes in adults with obesity and type 2 diabetes. A target trial is emulated using de‐identified electronic health records from TriNetX US. Dual therapy is compared with GLP‐1 RA, SGLT2i, and usual care using 1:1 propensity‐score matching. The primary outcome is all‐cause mortality at 12 months; kidney graft failure, rejection, complications, and infections are secondary. Sensitivity analyses included the global network, landmark, extensions at 24 and 36 months. Three matched cohorts are constructed, dual versus GLP‐1 RA (n = 4718 pairs), dual versus SGLT2i (n = 4282), and dual versus usual care (n = 3787). At 12 months, dual therapy is associated with lower mortality versus GLP‐1 RA (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.57–0.85), SGLT2i (0.59, 0.48–0.72), and usual care (0.52, 0.43–0.64). Infection endpoints are neutral or lower. Estimates are consistent across sensitivity analyses. In transplant candidates with obesity and type 2 diabetes, pre‐transplant GLP‐1 RA+SGLT2i use is associated with lower mortality than monotherapy or usual care. Prospective evaluation is warranted.